ProCE Banner Activity

New Treatments on the Horizon for Patients With HDV Infection

Conference Coverage
Clinical Thought
Now that the horizon is getting closer, our job now is to identify our HDV-infected patients and prepare them for treatment.

Released: July 22, 2021

Expiration: July 21, 2022

No longer available for credit.

Share

Faculty

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Supporters

AbbVie

Antios Therapeutics

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from AbbVie, Arbutus, Gilead Sciences, Intercept, and Salix and funds for research support (paid to her institution) from AbbVie and Gilead Sciences.